{"title":"Diagnosis and management of diastolic dysfunction in arterial hypertension","authors":"P. Blanch, R. Freixa-Pamias","doi":"10.1016/j.hipert.2025.06.002","DOIUrl":null,"url":null,"abstract":"<div><div>Diastolic dysfunction (DD) refers to impaired relaxation or filling of the ventricles during the diastolic phase of the cardiac cycle. Left ventricular (LV) DD is common in hypertensive individuals and is associated with increased morbidity and mortality, particularly heart failure with preserved ejection fraction (HFpEF). The pathophysiology of DD involves alterations in cardiac structure and function, neurohormonal activation, and vascular stiffness. Diagnosis is primarily based on echocardiography, and there are no specific treatment guidelines. Recently, treatments such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), GLP-1 receptor agonists, and finerenone have emerged, which may offer benefits in diastolic dysfunction and HFpEF. This review aims to present the pathophysiological mechanisms of DD in hypertension (HTN), its diagnosis, and its treatment.</div></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"42 3","pages":"Pages 237-246"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183725000388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Diastolic dysfunction (DD) refers to impaired relaxation or filling of the ventricles during the diastolic phase of the cardiac cycle. Left ventricular (LV) DD is common in hypertensive individuals and is associated with increased morbidity and mortality, particularly heart failure with preserved ejection fraction (HFpEF). The pathophysiology of DD involves alterations in cardiac structure and function, neurohormonal activation, and vascular stiffness. Diagnosis is primarily based on echocardiography, and there are no specific treatment guidelines. Recently, treatments such as sodium-glucose cotransporter 2 inhibitors (SGLT2i), GLP-1 receptor agonists, and finerenone have emerged, which may offer benefits in diastolic dysfunction and HFpEF. This review aims to present the pathophysiological mechanisms of DD in hypertension (HTN), its diagnosis, and its treatment.
期刊介绍:
La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.